still aosd - hospitalisthospitalist.jp/wp/wp-content/themes/generalist/img/...g ? &)h
TRANSCRIPT
��Still� AOSD8…�*+,/12-8
6457�����' �$��
��!3PGY4 %( ��3���)��� )����
�&3"�.203��+#���
0
60��� �+V!�5 4 5�-$(
8&'9
1S� ��)<"�:��
3/3 ."*#ANGFA>�,
→6�����%�7;,�⇒α-AQOH@GMKRJP?R1�TIELEDR0�UCPBEKR®V32�3>1S����
→U���V"�=��…
�� ��()���+�#�*��
� � ��
37-38℃�%��+�#�&��,�!���'��
→��$()���"…
⇒ ���
V��"WR5S.z?�AL�{
65!|9 �@R�z�L���3AL�{V�;"W
[tlZ_tbhyt 1H�1Uα-avtl^jrownu\wF�xmfqfewDzducfow®{3H�3UsdhvwFigs]p$,z[agkt®{17.5mg/BV[ut`yWP,|YXU;,|sh_\w�F�
V-'"W +|YXUQE|YX VSick ContactWYX
}Patient Negative~N/U��UT%U�1U7/U:/U�0UK4/U6C/U�(*U���/U#��U�G)�U�J2&U=���UO><UI�M�U8��
G�?�&)H
�<VSU GCS E4V5M6�! 37.9℃F� � 18�/�F2� 94�/��F:� 137/82mmHgFSpO2 97%Y�� Z
BC=[,.179+LJX"$�:LJF
,'17D�LJF4��#LJF
�����LJX+8�-LJF
��C=M1cm�N�*Q�ITWR053Q1K;POF>@�LJFC=%/ALJF
E4��*LJF($65�X�*LJ
#.G2�3A27 �564
�2�3�127 �564
*.G� D,3��653!'���653
Murphy��0�3)+�2�-��653CVA���653$����65
�"G�(653��653/�(&D��653
8C?;@C=:8CD>=B<9:8C0�
��G%NE�HX�Fn.p.3��"Barre�� n.p.3�"MMT �5/�53�"MMT �5/�53
�� ������
������
WBC 12700/μL TP 7.6 g/dL BUN 14.4 mg/dLNeu 83.3% Alb 4.3 g/dL Cre 0.71 mg/dLLym 10.0% Tbil 1.0 mg/dL UA 2.8 mg/dLMon 6.3% AST 42 U/L Na 135 mEq/LEos 0.1% ALT 34 U/L K 3.8 mEq/L����(-) LDH 267 U/L Cl 97 mEq/LHb 13.2 g/dL ALP 303 U/L Ca 9.5 mg/dLPlt 22.9�/μL γ-GTP 41 U/L CPK 42 U/L
%���& %���&
CRP 5.2 mg/dl pH 8.5���!��"T#-$ ��#2+$
� ��#+/-$�"� �"���#-$ ����#-$A����#-$ ��#-$
��� 20-29/HPF%���&�� �� 1-4/HPF%���& ��
&��Xp'���� ������ ���� ��� �
&��"#%'
�!���$��� ����� ��
"#%Murphy������ ����� ������ �
)�R�;�
Ø60���R+%] D*]<02*
Ø+%��[YZ\(�PL
�EAQ=�R43SGWTF�����U,6�.PKF>?"@7C�
ØB1$U#!�$X/�MW�9PL
Ø^8! �OS$)S��LNHWJ…_<�:�]8! ��9]� �]'�IVS
�VIP5�&(-(��9PL
��"���
%$-'�� ���� ����
⇒#()#,*+&.�NSAIDs�!�����→������!��
Clinical Question�������������������
��� �������
Clinical Question
�������� ��������
���� � D�%D
���� �B� �C8)��928
$�6�1;&���3,;4!.:<;)
# (�5)��0-;�"��3,;
Ø'���7����5�5 �)��)
>A=?@���/:5;
*Immunol Allergy Clin North Am2004;24:357-371+
*Am Fam Physician2006;74:1883-1888+
��� �� J��J
���
• ��<D=.'&D. HSV HSV-1H66.7%I"HSV-2H27.8%I
• ?&*;B/?
• ��
• ������
• C���'&D.• +&3A)E'&D.
• 83����'&D.
�
• 7D92GD!
• 80F3&F
• NSAIDs• =5,CF
• :(61%-F
• .D>F%@4
#J Med Virol2003;71(3):423-428$
#Am Fam Physician2006;74:1883-1888$
#Dermatol Clin.2003;21:195-205$
����� 0����&��0
-,����$��+)*(�& !��
@����
.,��#$'
/,��!�%��"'�Curr Probl Pediatr.2001;31:207-234
�McGraw-Hill.2003:585-596
������ C��!2�$C
A@��3�2� %-�'1�"�/��/��/05
B@(9?8:;���)
( ����)6�.5
3�,4�>� -�"�>&1����>��#-"�<=7
*Clinical Dermatology.2000:146-151+
������� G ��#:�(G
DC�,9��;$�<'"
EC����0�4?17=/>
A�%;���9+2@?B
FC )�8393G5&*6!��9��A���5?17=/>B -Dermatol Online J.2003;9:1.
-Dermatol Clin.2003;21:195-205.
���#� ?,�?
Ø ���#�mimic'.�
Stevens-Johnson ��$
��(�
���-���
���%����
Sweet�
Rowel��$=SLE>
���
:138;6:+����
49<7;&!"�
���*���
) �
21<5���
��Still�
/Up To Date “Erythema multiforme:clinical features, and diagnosis” 0/Korean Journal of Dermatology2009;47(8):979-9810 /J Invest Dermatol.1999;113:808-8150
������ >��!>
�����2��3" ��(64��2
��1+.�87
ØHSV�����1�,7���2 ;:=<�167��3��2��9�'-�)0&
�����2�*3����25/����
/%7
#Up To Date “Erythema multiforme:Management” $
#Br J Dermatol.1993;128:542$
#Up To Date “Erythema multiforme:Management” $
�����*� ^�%3^
\0"�] Z'-!�>@ or �,).!�92�[
• $B�#>0�D(&=:;��<��
• '-���4�#→��JVNJLOWFP4+��QLMSX
• $D�8�,�?CE→UPHFX4KRGXQPTSX41/���D A��JVNJLOWFPIVY897�
5Up To Date “Erythema multiforme:Management” 6
��(��2! o%-@o
m=,�n k�0 S718+�[#LY��l
• =�S18+�[#LY9�KM��2!�5RSV3_ai\cS3��[ �
⇒3fhcd`jk40o60mg/"l[2o4;RZMX)'
:S?E]ebj_TQIA*�&�[<�/R��
LYNJOA*�S���GWU.�S�4$>S
g_^[��LY6�HDYPEF��S��DXBJ Oral Pathol Med.1995;24:9C BBe J Dermatol.1995;132:267C
BJAMA.1983;249:2810C
Clinical Question
����������
)���*;&�
���A�56.@ �<� �: �1
�729.481.
⇒�';�$8�:��A#!5(��="���7��56.3��-?B
��;%�C���0�"�D:>@��7
&�A�/6.3
+Up To Date “Approach to the patient with myalgia” ,
S2<,TYDDx
UUp To Date “Approach to the patient with myalgia” V
�K/
[Zo_��+R7F��R_ipks`��R
:92,+R��'�+�;t2,�?>Q"uR
n[la��.2,+R�.�2"r0C2"R
O4n[laR�K�]nbldsc_R>�O4+R
H3"RPL�+R�J�2)�R�H*R@��R
&%B =��+R�����!#R18��(,R
G�t$X_`aq6Rj\efoh`souR
51/I�RA- etc
��/N�WM R��R�E�2"R2D�(,+�;R
2��R^qgsdmqd+�;RA- etc
1��7�-�(2�-� :AC:GDE;I 200mg 6,�30
AH>=?F100mg 2,�2 ��LAH@BGI®8��M
→37N39℃�7��0�.�0� ���
3�� �%64 WBC 12400/μL0Hb 13.0g/dL0AST 65U/L0ALT 62U/L0ALP 405U/L0γ-GTP 134U/L0CRP 12.0mg/dL0%� 104L!")�+���0����J/�M
→$*<>K &9$#�'��53
���%�2�(39<3?=>4C��
4�� 9A8:?C02$�2 /�#
��.'-��…
→����"�>4@;C&TSH&freeT4&ANCA&EBV �&CMV �
5�� ���57D� *10���!,)
��>6BD-+… WBC 18700/μL&AST 45U/L&ALT 48U/L&ALP 573U/L&γ-GTP 216U/L&CRP 16.3mg/dL&�� 114
386!".�0���2����
&/A1�/-CT�)<!2"2'2#2�$2�$6
�+�� *54
<��5:;9�%�54
?,�7(��� �@
DBECF 3900 ng/ml2P-ANCA=->2C-ANCA=->TSH 1.08 µIU/L2freeT4 0.87ng/dL2EBV<CMV���2T-SPOT=->2HBc��=->2HBs��=->2HCV��=->
5�� /��"%���? '�&/
��3�2.,:>6$��-��
;5<8>)�*��*��*
WBC)�*(�*!�#��
⇒ �794=� AOSD0�#�+1
6�� ��'�
A&)>89=?:>C-DA!��"41%,�6$73.
37E39℃�5 ��<;B@*�0-+�A� �5��0.…
��6#�2�(��-
���4��3��
/����
7� ��%�>���;"��9$0A
�'9�54…#+1?;
��EFCH�2�=$0?B6
�(��;�.9��9/@…��EFCH�973���:GED=
$�5�,���2 &8��
8� 9�,!:/A�-<)*
Clinical Question
��Still� AOSD������� �
AOSD Y�/Y
��" Still�Wadult-onset Still disease : AOSDXH"�85)�8$�G3 �P��D@N8�1#&E��C;N
�H��C-�G7*��F�+A>LO
B<N=82�. ��H6�C;N
���G���D?B4/C;M8�3G%'
CK���G�D?B6%PJ8UQTR��"(! 8��UVS,D�I�/E��C;N
9BMJ Open .2013;3:e003971:
9���0.2015;104:2143-2148:
9���0.2015;104:2143-2148:
AOSD ?�?
�(4/06AOSD3'�172169�5&�#"��5��<���>��= 8>158 � 4.8%>95.2%#"���+ 46,19 ��5�� 121/168� 72.0%
-Rheumatol.2015;25:393-400.
��� "�� *�<%=��)$� 2/158 1.3%��Still! 0/159 0.0%)$;8:9 7/157 4.5%�5% �� � 3/157 1.9%
AOSD 4���4
ØAOSD#��!"$�"���
1. ����
2. ����2� ��0����#��3
3. -(.,%1*0T��#��
4. )&+'&/#����
⇒�)&+'&/���Immunol Res.2015;61:53-62
AOSD J����J+�( E��#(FI��(E��� F
T@B=�E�2Th1F��� ?8A>4D:C����
.95<75B' EIL-18,IL-6,IL-8,TNF-α,IFN-γ,M-CSF etcF
G��Still�3&��H!�/,$�/%-�/"'���/� �)/.>6@;B' etc
0���*.2007;96:2206-22131
AOSD ]&�$"]2�/� X�"*/�Y\# /�X�����Y
TSUP!X�@Th1Y�� RJTQEWLV�!��
6KFOIFU.'XIL-18,IL-6,IL-8,TNF-α,IFN-γ,M-CSF etcY
Z��Still&A-��[(�74+�7,5�7).!��7�'�076QGSMU.' etc
8���1.2007;96:2206-22139
VAOSD@;:> �*V148.9pg/mlDINOHQ?=C?7��AOSDD�.'<B3�=CA@��88%7 %�78%8J Rheumatol.2014
;41(6):118-1239
AOSD *��!%&'$*
AOSD �������(���� ���etc)
AOSD mimickers���
AOSD�����#"!��
�����
1st line �
2nd line � �J.Autoimmun.2014;48:34-37�
AOSD 0��"0
ØAOSD����)!�(%)(%&*�'��)����Asanuma.169�/
Wounters.28�/
Masson.65�/
Pouchot.62�/
Fautrel.72�/
� � 59 68 68 92 38�� 25 75 62 84�� 92 100 94 100 82�� 51 68 69 94��� 83 100 100 64,-+��� 45 54 48 74 32�� 62 54 85 87 51�� 32 14 22 55 32�� 25 15 53� 3 25 23 37 15
#Ann Rheum Dis.2006;65:564-572$#Rheumatol.2015;25:393-400$
AOSD J��1J
ØAOSD=�� H�����I
• CGEFDFB%=���="�
• ��2$*�-<��92&��5@H�0/?$,�<��>!I
• ���<��92'��<%#� A�8:�+
• ��7 ;6
• Kobner�).� CGEFDFB��
3���(.2007;117:2471-24784
AOSD ����
ØAOSD�� ����������
• � ��� �Clin Rheumatol.2000;19:389-391�
�Narvaez Garcia et alMedicine.2017;96:11�
AOSD ����
ØAOSD� ���������
• ����� �� �J Dermatol .2006;33:55�
AOSD �����
ØAOSD�� ���� �����
• �������� ��
�Narvaez Garcia et alMedicine.2017;96:11�
AOSD 9���9
ØAOSD#�� 7����#���8
• �������
7����)163(&5�/2',6.���8
• ���#��$��
• 0+5 �%�"�'45*-63����
Arch Dermatol.2012;148:947!
J Eur Acad Dermatol.2005;19:360!
J Korean Med Sci.2002;17:852!
AOSD "� �"
ØAOSD��� ��������!
• ����
• Sweet�����
• �������������
�Clin Rheumatol.2004;23:92�
�J Am Acad Dermatol.2004;50:590�
�Eur J Dermatol.2009;19:621�
AOSD �����
ØAOSD������(%)
�� Pouchot�62��
Masson�65��
� 82% 69%
�� 73% 67%
�� 55% 38%
PIP 47% 44%
� 44% 29%
� 40% 24%
�� Pouchot�62��
Masson�65��
MCP 35% 42%
MTP 18% 11%
11% 7%
DIP 10% 9%
PIP 3% 0%
���� 3% 4%
�Ann Rheum Dis.2006;65:564-572�
AOSD ?���"?
�(4/06AOSD3$�172169�5#�!����" )�+� %
�!��=>1�> 131/165 79.4
���=>80%> 118/165 71.5
%!=Hb<10g/dL> 68/169 40.2
!��� =<15�> 23/169 13.6
&��'=≧40mm/h> 113/164 68.9
,:8;9<!� 146/165 88.5
:8;9<>3000ng/ml
99/165 60.0
!����" )�+� %
� �!� 32/169 18.9
�Alb!� 107/139 77.0
�*� 122/165 73.9
CRP,� 151/165 91.5
PF)� 33/164 20.1
����)� 42/163 25.8
-Rheumatol.2015;25:393-400.
AOSD K�� #K
IAOSD5�'�J• �$�&�677%4��2*�%�&�665%4��3;
• LDH6AST8ALT9:7��/(.��-;/*=>A@>D6LD4,5/�0� ��51<;
IAOSD5"�C?EBF�J"�C?EBF�Gng/mlH
��Still� 13910)3640��!��� 329)26�� 115)8
+Hepatogastroenterology.2003;50(49):192-195,
+ J Rheumatol.1997;36(5):608-609,
AOSD 5����5
3AOSD)����4
����(�+��+ �*.,-*%&…
ØAOSD)PMR,��+FDG-PET&�'),��$/
• AOSD →� !��!120�!��+��
• PMR →����,����+��
"Mod Rheumatol.2014;24:645-650#
AOSD e9��!e
Ø YamaguchiZU�A�!G�?.HB*"c≧39℃F1:;���0dC</(c2:;���0dE� ,-%D80%��U��#��\�M+8#��c≧10,000/μldG�?.HB�@(Cab_/64K[LV56E2 3$�Da]`^��>�NYW����>�
G=�?.HB��' C��6) E7&
2?.��U�?.\X1?.�5?.��SFAOSDT�Ac�QRP=�?.V=Od
IJ Rheumatol.1992;19:424-430J
AOSD 5����5
ØYamaguchi.,����+"!(���2����#'��� 5��+(���96.2%����92.1%*�� /
�AOSD70�*�AOSD140�+%(�4',����3Yamaguchi�Calabro�Cush�Reginato42��%&��)�Yamaguchi.,��$��78.57%����87.14%*�-��+�10*,�� /
�J Rheumatol.1992;19(3):424-430�
�J Rheumatol.2011;38(4):741-746�
AOSD e9��!e
Ø YamaguchiZU�A�!G�?.HB*"c≧39℃F1:;���0dC</(c2:;���0dE� ,-%D80%��U��#��\�M+8#��c≧10,000/μldG�?.HB�@(Cab_/64K[LV56E2 3$�Da]`^��>�NYW����>�
G=�?.HB��' C��6) E7&
2?.��U�?.\X1?.�5?.��SFAOSDT�Ac�QRP=�?.V=Od
IJ Rheumatol.1992;19:424-430J
AOSD ��� �����
AOSD����������
�J Autoimmun.2014;48-49:34-37�
AOSD {I)� mimicker{ØL�Y]XAOSD mimickersy��+z `_sf��+wCMVTEBVTHPVTS(TP(T�E
�:�@"T^jkT_umsaueTlq_umsaueTHIV etcxT7C��+w$[����A"xT3C��+w ��3C+xTo_dnqgoT8�
y>-�z ��rul>T0D*TD5rul>T>-N��w�.W��TQH.T2?.T<.T'%@�O.x
yB�*z D5"w$[86��/�="TR�* etcxT��J6r`ohTD! �M�r`ohTSLETr`oh��/4,+Tr`oh# etc
yZ\�z �,PTbpifsou*TD&GQ+�9T���'%@"T;"T�?K�ctvu* etc
U�1�F.2006;116:429-436V
AOSD W��#?1�W
ØAOSD64��#?� �
0!28#�+ HPSRHTPEVJ��#�+ MAS�$�0'��� DIC0��0�����)�" TTP@AD�-.�0
�&�
�#,�
��%3#�+
-90�
LUQOVM
*���/�
��/�
FSTGNVIK
0����0'7�
>5(=<CB��# :Clin Rheumatol2014;33:305-314;
AOSD X���A,�X
ØSMURIWO����" MAS• SMURIWOCT $A��>NJQLJVA/?��@DE(�.0H7;:��
• AOSDA10X15%@��:F>8GF
• ' �*>9<��3#%&H�:
• +�B2�!��A(���3RKTPV��312��=A(�.0�@<)6
4Mod Rheumatol.2015;25:393-4005
4���-.2015;104:2143-21485
4J.Clin.Immunol.2007;30(6):428-4315
4���-.2015;104:2143-21485
AOSD U��>'�U
SAOSD=�8@MAS>)�T• ���QCPKOEPG/EBV/CMVR• %�Q�NDLJ��>.�/IOKBFMHPR
SAOSD=MAS�A�3?5#,T• AOSD;6:! 6<2>=&�4��6:2<2• ��6:29&�4��=*79 • +�>��=�6<2 • -�>$���A"69
0J.Rheumatol.1992;19:1425-14271 0J.Clin.Rheumatol.2001:7;252-2561
0���(.2015;104:2143-21481 0J.Clin.Immunol.2007;30(6):428-4311
AOSD @��4"�@
Ø �9<;:=
• AOSD5 �9<;:=8�.6/*>%�54%?
• ���6NSAIDs4��1��6��8,0/-2+)7
�����4&*��35AOSD���4� 8��$3/7 !+)7
'J Rheumatol.1990;17(8):1058-1063(
'���#.2015;104:2143-2148(
'J Rheumatol.1990;17(8):1058-1063(
AOSD R�4LKJF2�9R
ØAOSDD1�=H@100�I�3D>@$5I��?G��EA<BF�/
• �4LKJD�%� F!6EA<B2���4LKJ…�0127 I�1�C2�P12���Q
�� ).� (� ����
�.� NOM#, +, ',or'�*���8� "&� -� WBC>15000/μl
:BMC Medicine.2016;14:194;
AOSD A >=;5��&A
ØAOSD3��,9/100�:��3-/�":��.8��40*15��
• ��% 45.35�• >=; � 6.11• 100��16�+���#�
AOSD$!2��-/
' >=;≧7�2 >=;@7�67�4AOSD$!��?><�� (BMC Medicine.2016;14:194)
AOSD 0� 0
PSL 0.501mg/kg/�������&(.$)*-& �!���102mg/kg/�
MTX���
Systemic AOSD�������
IL-1β�IL-6�IL-18�CRP�+%,'/↑
Chronic articular AOSD����� "#������IL-18�+%,'/↓�IL-8�IFN-γ↑
TCZ
IL-1���
TCZ TNF-��
1st line
2nd line3rd line
�Ther Clin Risk Manag 2014;11:33-43�
AOSD K1st lineK
Ø3,2:=F7>�
⇒AE>?;FG 0.5K1mg/kg/�62K3��
ØMAS4DIC/.1"��*(54��:=F7>0 +5��*��/
⇒B<DAE>?;FG@D:��I1g/body div 3�$J
Ø:=F7>1�#:89CHD2%
����-������6��0!��)&��� .2015;104:2143-2148'
1st line
AOSD V1st lineV
!%1��B8:K���AOPRNQ��D
!%���M��;=2�� 8IE&C
�G0,A�"��?6K@��;L>7K3
S���)��TWBC > 3�/�2* �/USOPRNQ���)2&M(J.<
⇒��BMTXH$#�'+�M�-<F94Rheumatol Int.2012;32(5):1291-12985
4Clin Exp Rheumatol.2014;32(1):28-335
AOSD R2nd lineR
ØGHOBJ����9����8�;43<9
:7./*MTX/�.>A@16/ .⇒LIINCEQIMTX 8R16mg/%
�MTX:GHOBJ9�&/(7��='!�/�"2@�8 0�.>A*�8��9�
5:���/).
Ø �/�"2@��*�#��*MAS9��⇒FDOGKMP CyA/��69�-?
+���$.2015;104:2143-2148,
+J Rheumatol.1999;26:373-378,
+Mod Rheumatol.2009;19:57-63,
2nd line
AOSD W3rd lineW
��59�>SFTR>@SUIL-V1#�/ �&�"624��1<4.;
�'59�IL-6����JPBDMLUTCZV/�: 0��1<4.;
⇒JPBDML TCZ 8mg/kg=4%*+5��
���)��7MAS=��3;�/�1<4.;⇒I@AOFESKQNGS(?CHQ
or CyA8�!��/��1<4.;
3rd line
,Arthritis Care Res.2011;63(1):155-159-
,Best Prac Res Clin Rheumatol.2014;28:277-292-
,���$.2015;104:2143-2148-
AOSD %��$�%
ØAOSD!��"� ��#������� Monocyclic pattern������� Polycyclic pattern������ Chronic pattern �������# �����
�������
➂������
�Arthritis Rheumatol.1987;30:186-194�
AOSD A!+@��A
.Clin Rheumatol.1991;10:294-297/.J Rheumatol.1990;17:1058-1063/
• 19��9:7��54-��%�• 2?�A1�7�'3=���
•�(��9��>&�#<*3•#<*3�8)��2-�'3= ��(�
• 1���9!+7-�"�, �>�0•�, ;$, 8�����>163��, ��
.Arthritis Rheumatol.1987;30:186-194/
24%
41%
35%
=��Kfeed back>;AOSDP�A,��/
⇒YamaguchiMK�9��7$37$Z 7$27$P�FE\
126%��)EN"�<�8!&!
� KI@S[WYUYR-#�
"��J��D0�H�1EN#�
WBC>1�]Neu>80%^VQXTY:�]>3000ng/ml^CRPZ.�:�<*+3'5(��
�4HL25%%�K�H?NB<
��HL60_80%K�BCOG@N
�
�
�
'��/feed back(&AOSD mimickers/#
⇒���@ ���@-/����0����+2
54>7����$�
��%$�
;46:<8; !$�
TSPOT$���*10 ���/=?9�3�)��.,"�����0.,
ANCA$�
A'�Mfeed backB>AOSD �'M4�
⇒$�#JNHPS?MAS?DIC?TTP?/03?�*"L2HIDR�1�N)�(JNKDF…,6� �L �\'."L2R�1�CQ
WSYUZ��CRF…3%!�O5=�KG3��!�/��&�KG�;�XVT[Nsinus rhythmJ�:<-�KGCTJN/8L�PEK&�9�KG.7+N�@L����…
+��/feed back,*�'432/&�
⇒�'4327�8→���%�.�)-10…9
�� �$� �� ����
$� 675�" !" �"or�� ���(� ��� #� WBC>15000/μl
5!�Cfeed back6Ø-�)0C.�9ED��IMHT @<>%$A7@*8F:…
u��C!�C#�D/�?�+1�2B��→��IMHT BD&⇒�����(�mimic
u��?JUILRW®333 /���XJUILRW®13BQLSLKW0.75mg 43 /�
= PUNOKVW�'5mg43/�Y→����:2"B�;G>7= ,�
Take Home Message��%"L�6�*;J&!=3+1�G(#
L-E<��B��PQMT$L/�@�9J
��PQMT$A,�B48C=0�,�
��PQMT$A(#B&!�@�.�@
DHKJ:>7�5732��'?(#F4I3
�� �)��A(#L-EJ:>74J
� ?PQUNR��B���V�&ASPO
>?I6J